Profile of soluble cytokine receptors in Crohn's disease

[en] Introduction: Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease ( CD). The aim of the study was to examine the profile of sCRs in CD patients and their modulation by infliximab and corticosteroids. Methods: We prospectively examined active CD patients (aCD) treated with either infliximab (n=21) or corticosteroids (n=9), CD patients in clinical remission (rCD, n=20), ulcerative colitis patients (UC, n=24), and healthy subjects (HS, n=15). Cultures of colonic biopsies were also examined from CD inflamed (n=8), CD non-inflamed (n=7), and healthy mucosa (n=8). Levels of tumour necrosis factor alpha (TNF-alpha), soluble TNF receptor I (sTNFRI), soluble TNF receptor II (sTNFRII), interleukin 1 beta (IL-1 beta), soluble IL-1 receptor I (sIL-1RI), soluble IL-1 receptor II (sIL-1RII), IL-6, soluble IL-6 receptor (sIL-6R), and sgp130 were measured using ELISA. Results: Higher levels of sTNFRI (p<0.05, p<0.01), sTNFRII (p<0.01, p<0.01), sIL-1RI (p<0.05, NS), IL-6 (p<0.01, p<0.01), and sIL-6R (p<0.05, NS) were observed in aCD compared with rCD and HS. Interestingly, sIL-1RII (p<0.05, p<0.01) and sgp130 (p<0.01, p<0.01) were profoundly decreased in aCD compared with rCD and HS, and were negatively correlated with CRP. Deficient production of sIL-1RII was specific to CD ( not observed in ulcerative colitis), and was further confirmed at the mucosal level. Infliximab decreased sTNFRII at one and four weeks (p<0.05) and enhanced sIL-6R levels at one week (p<0.05). Corticosteroids increased sIL-1RII levels at one week (p<0.05). Conclusion: CD is associated with dysregulated production of sCRs. Deficiency in sIL-1RII and sgp130 may be essential to CD pathogenesis. Their replacement through the use of fusion proteins could represent future alternative therapeutic strategies for CD.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Gustot, T.

Lemmers, A.

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Nicaise, C.

Quertinmont, E.

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Roland, S.

Van Gossum, A.

Deviere, J.

Franchimont, D.

Language :

English

Title :

Profile of soluble cytokine receptors in Crohn's disease

Publication date :

April 2005

Journal title :

Gut

ISSN :

0017-5749

eISSN :

1468-3288

Publisher :

B M J Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

488-495

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 October 2009

Statistics

Number of views

58 (3 by ULiège)

Number of downloads

17 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal transaction. Annu Rev Immunol 1992;10:295-331.
Fernandez-Botran R, Chilton K, Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease and therapy. Adv Immunol 1996;63:269-336.
Mackiewicz A, Wiznerowicz M, Roeb E, et al. Soluble interleukin-6 receptor is biogically active in vivo. Cytokine 1995;7:142-9.
Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp 130 in human serum possessing a potential to inhibit signals through membrane-anchored gp 130. Blood 1993;82:1120-6.
Carlo E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-17.
Allison MC, Poulter LW. Changes in phenotypically distinct mucosal macrophage populations may be prerequisite for the development of inflammatory bowel disease. Clin Exp Immunol 1991;85:504-9.
Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
Best W, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the CDAI. Gastroenterology 1979;77:843-6.
Sandborn WJ, Hanauer SB. Infiximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.
Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the World Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-8.
Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumor necrosis factor-α, interleukin-1 β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
Wardle TD, Hall L, Turnberg LA. Use of coculture of colonic biopsies to investigate the release of eicosamoids by inflamed and uninflamed mucoso from patients with inflammatory bowel disease. Gut 1992;33:1644-51.
Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-18.
Tilg H, Dinarello CA, Meir JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators, Immunol Today 1997;18:428-32.
Symons JA, Young PR, Duff GW. Soluble type II interleukin-1 (IL-1) recetor binds and blocks processing of IL-I β precursor and loses affinity IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-18.
Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995;40:365-94.
Spörri B, Bickel M, Dobbelaere D, et al. Soluble interleukin-1 receptor-reverse signaling in innate immunoregulation. Cytokine Growth Factor Rev 2001;12:27-32.
Svenson M, Hansen MB, Heegaard P, et al. Specific binding of interleukin-1 (IL-1) (and IL-1 receptor antagonist (IL-1 ra)) to human serum. High-affinity binding of IL-1 ra to soluble IL-1 receptor type I. Cytokine 1993;5:427-35.
Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993;82:1120-6.
Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995;36:45-9.
Louis E, Belaiche J, Van Kenseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997;9:939-44.
Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nature Med 2000;6:583-8.
Schöbitz B, Pezeshki G, Pohl T, et al. Soluble interleukin-6 receptor augments central effects of II-6 in vivo. FASEB J 1995;9:659-64.
Bauer J, Martin Bauer T, Kalb T, et al. Regulation of interleukin-6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression of human hepatocytes. J Exp Med 1989;170:1537.
Sanceau J, Wijdenes J, Revel M, et al. IL-6 and IL-6 receptor modulation by IFNγ and tumor necrosis factor-α in human monocytic cell line (THP-1). J Immunol 1991;147:2630-7.
Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 1994;5:563-71.
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor (in vitro and in vivo). Proc Natl Acad Sci USA 1992;89:4845-9.
Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxemia in inflammatory bowel disease. Gut 1995;36:897-901.
Hudson M, Gallati H, Ryff JC, et al. Serum TNF receptors p55 and p75 in Crohn's disease. Gastroenterology 1993;104(suppl):A715.
Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9.
Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-α are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6.
Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17.
Hyans JS, Treem WR, Eddy E, et al. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:233-6.
Lantz M, Malik S, Selvin ML, et al. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in human. Cytokine 1990;2:402.
Cope AP, Aderka D, Wallach D, et al. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 1995;84:21-30.
Leeuwenberg JF, Dentener MA, Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. J Immunol 1994;152:5070-6.